Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

C

CancerCare Manitoba

Status and phase

Completed
Phase 2

Conditions

Multiple Myeloma
Lymphoma

Treatments

Drug: Plerixafor
Other: Observation: Nonintervention

Study type

Interventional

Funder types

Other

Identifiers

NCT01037517
CCM-002

Details and patient eligibility

About

Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful stem cell collection. OBJECTIVES To determine if plerixafor when administered on the day prior to planned autologous collection on first mobilization attempt in those with a peripheral blood CD34 ≤ 10X106/L will: increase the number of patients successfully collected in one day increase the number of patients successfully mobilized on first collection attempt is cost neutral within a Canadian setting

Enrollment

52 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants must be 18 years of age or older
  • Patients must be able to provide written consent
  • Participants must have a diagnosis of lymphoma or multiple myeloma and be undergoing autologous stem cell mobilization for the purposes of ASCT
  • Females of child bearing age will be asked to use an approved form of contraception

Exclusion criteria

  • Patients who are pregnant or breastfeeding
  • Patients whose creatinine ≥ 250 μM
  • Serum AST, ALT or total bilirubin >5X upper limit of normal
  • Acute infection

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

52 participants in 2 patient groups

Successful Mobilizers
Active Comparator group
Description:
Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
Treatment:
Other: Observation: Nonintervention
Poor Mobilizers
Experimental group
Description:
Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
Treatment:
Drug: Plerixafor

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems